The self-micro-emulsifying delivery system from Pharmako enhances bioavailability of Omega-3 ethyl esters in healthy subjects under low-fat diet conditions, new study says
A new study has demonstrated that AquaCelle, a patented self-micro-emulsifying delivery system (SMEDS) from Pharmako Biotechnologies, increased total absorption (AUC0-24hrs) of Omega-3 (EPA + DHA) ethyl esters (EE), in humans by six-fold compared to the control.
The randomised, double-blind study measured the uptake of EPA (Eicosapentaenoic acid) and DHA (docosahexaenoic acid) EE over 24 hours in healthy adults under low-fat diet restrictions.
Participants were randomised into two groups, receiving either the SMEDS AquaCelle fish oil formulation or the unformulated fish oil EE. The novel delivery system demonstrated a significant improvement in the oral absorption of Omega-3 fatty acids without requiring a high-fat meal.
This study highlights the superiority of AquaCelle as a delivery system for significantly improved absorption of lipophilic ingredients
“It is commonly known that Omega-3 absorption is best achieved with a high-fat meal. However, because many individuals require low-fat diet restrictions, oral bioavailability is incomplete and requires higher doses,” said George Kokkinis, Co-Founder/Technical Director at Pharmako. “This study highlights the superiority of AquaCelle as a delivery system for significantly improved absorption of lipophilic ingredients.”
Pharmako explained that AquaCelle technology is customisable to optimise bioavailability and dosage formats of several diverse, active ingredients.
Graphic abstract: Application of intelligent formulation design has the ability to address the poor bioavailability and improve the fasted state bioavailability of fish oils
AquaCelle has more than ten human pharmacokinetic and clinical studies underway and is also validated through laser light obscuration and dynamic light scattering (DLS) analysis. Besides, AquaCelle can be formulated for use in multiple product sectors, including nutraceutical, cosmeceutical, pharmaceutical, food and beverage, as well as pet and veterinary applications.
“We are thrilled about the results of our technology. Omega-3s have many health benefits and reducing the relevant dose or improving its efficacy provides great benefits to both the manufacturer and the end consumer, said Eric Meppem, Co-Founder/Technical Director at Pharmako Biotechnologies.
The study and its results have been published in the European Journal of Nutrition.
Pharmako is a science-based Australian company with a global footprint specialising in innovation and unique product development. The company's technology focuses on significantly increase the bioavailability and functionality of various lipophilic active ingredients for the nutraceutical, cosmeceutical and functional food and beverage industries.